GT200900292A - "inhibidores de cinasa p70 s6" - Google Patents

"inhibidores de cinasa p70 s6"

Info

Publication number
GT200900292A
GT200900292A GT200900292A GT200900292A GT200900292A GT 200900292 A GT200900292 A GT 200900292A GT 200900292 A GT200900292 A GT 200900292A GT 200900292 A GT200900292 A GT 200900292A GT 200900292 A GT200900292 A GT 200900292A
Authority
GT
Guatemala
Prior art keywords
kinase inhibitors
inhibitors
methods
pharmaceutical formulations
invention refers
Prior art date
Application number
GT200900292A
Other languages
English (en)
Spanish (es)
Inventor
Robert Dean Dally
Jianping Huang
Sojan Joseph
Timothy Alan Shepherd
Christian L Holst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900292A publication Critical patent/GT200900292A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GT200900292A 2007-05-11 2009-11-10 "inhibidores de cinasa p70 s6" GT200900292A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
GT200900292A true GT200900292A (es) 2011-06-24

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900292A GT200900292A (es) 2007-05-11 2009-11-10 "inhibidores de cinasa p70 s6"

Country Status (33)

Country Link
US (2) US8093383B2 (https=)
EP (1) EP2148880B1 (https=)
JP (1) JP5503532B2 (https=)
KR (1) KR101088219B1 (https=)
CN (1) CN101679439B (https=)
AR (1) AR066344A1 (https=)
AU (1) AU2008251692B2 (https=)
BR (1) BRPI0811212A2 (https=)
CA (1) CA2687265C (https=)
CL (1) CL2008001230A1 (https=)
CO (1) CO6241109A2 (https=)
CR (1) CR11106A (https=)
DK (1) DK2148880T3 (https=)
DO (1) DOP2009000257A (https=)
EA (1) EA016445B1 (https=)
EC (1) ECSP099721A (https=)
ES (1) ES2483726T3 (https=)
GT (1) GT200900292A (https=)
HR (1) HRP20140611T1 (https=)
IL (1) IL201564A (https=)
MA (1) MA31433B1 (https=)
MX (1) MX2009012075A (https=)
MY (1) MY154898A (https=)
NZ (1) NZ580423A (https=)
PE (1) PE20090887A1 (https=)
PL (1) PL2148880T3 (https=)
PT (1) PT2148880E (https=)
RS (1) RS53451B (https=)
SI (1) SI2148880T1 (https=)
TN (1) TN2009000446A1 (https=)
TW (1) TWI423805B (https=)
UA (1) UA99284C2 (https=)
WO (1) WO2008140947A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
BRPI0921840A2 (pt) * 2008-11-11 2018-10-09 Lilly Co Eli produto compreendendo o composto inibidor de p70 s6 quinase e inibidor de mtor, composto inibidor de p70 s6 quinase e uso do mesmo
EP2355821A1 (en) * 2008-11-11 2011-08-17 Eli Lilly and Company P70 s6 kinase inhibitor and egfr inhibitor combination therapy
SI2396307T1 (sl) 2009-02-11 2015-02-27 Merck Patent Gmbh Novi amino azaheterockliäśni karboksamidi
JP5763636B2 (ja) 2009-08-07 2015-08-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規なアザ複素環化合物
EA020151B1 (ru) * 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
CA2788678C (en) 2010-02-03 2019-02-26 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
AU2011282684B2 (en) 2010-07-29 2015-05-21 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
LT2643313T (lt) 2010-11-24 2016-10-25 Merck Patent Gmbh Chinazolino karboksamido azetidinai
US9321760B2 (en) 2011-09-12 2016-04-26 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
PT2755965T (pt) 2011-09-12 2017-11-02 Merck Patent Gmbh Novas imidazol aminas como moduladores da atividade quinase
EP2892534B8 (en) * 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9580443B2 (en) 2012-11-16 2017-02-28 Merck Patent Gmbh Heterocyclic derivatives as modulators of kinase activity
EP2920154B1 (en) 2012-11-16 2017-10-11 Merck Patent GmbH Novel imidazol-piperidinyl derivatives as modulators of kinase activity
NZ706418A (en) 2012-11-29 2019-09-27 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
AR095202A1 (es) * 2013-03-11 2015-09-30 Merck Patent Gmbh Heterociclos como moduladores de la actividad quinasa
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909629C (en) 2013-04-17 2022-12-13 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105377299B (zh) 2013-04-17 2018-06-12 西格诺药品有限公司 用于治疗前列腺癌的包含二氢吡嗪并-吡嗪化合物和雄激素受体拮抗剂的组合疗法
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
NZ629486A (en) 2013-05-29 2017-11-24 Signal Pharm Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9771369B2 (en) 2014-03-04 2017-09-26 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3125935B1 (en) 2014-04-03 2019-10-23 Merck Patent GmbH Combinations of cancer therapeutics
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
TWI787284B (zh) 2017-06-22 2022-12-21 美商西建公司 以b型肝炎病毒感染表徵之肝細胞癌之治療
WO2022101459A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
EP2037931A2 (en) 2006-04-25 2009-03-25 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
TW200848053A (en) 2008-12-16
UA99284C2 (ru) 2012-08-10
RS53451B (sr) 2014-12-31
MX2009012075A (es) 2009-11-19
WO2008140947A1 (en) 2008-11-20
PT2148880E (pt) 2014-08-28
SI2148880T1 (sl) 2014-07-31
BRPI0811212A2 (pt) 2014-10-29
ES2483726T3 (es) 2014-08-07
PE20090887A1 (es) 2009-07-13
CN101679439A (zh) 2010-03-24
HK1140767A1 (en) 2010-10-22
CR11106A (es) 2010-04-12
DK2148880T3 (da) 2014-06-16
NZ580423A (en) 2012-02-24
PL2148880T3 (pl) 2014-10-31
KR20100005710A (ko) 2010-01-15
US8093383B2 (en) 2012-01-10
JP2010526814A (ja) 2010-08-05
US20090163714A1 (en) 2009-06-25
IL201564A (en) 2014-08-31
EP2148880A1 (en) 2010-02-03
MY154898A (en) 2015-08-28
TN2009000446A1 (en) 2011-03-31
AU2008251692B2 (en) 2012-10-11
ECSP099721A (es) 2009-12-28
DOP2009000257A (es) 2010-03-31
EA016445B1 (ru) 2012-05-30
AR066344A1 (es) 2009-08-12
EA200971051A1 (ru) 2010-06-30
HRP20140611T1 (hr) 2014-08-15
EP2148880B1 (en) 2014-05-28
US20120071490A1 (en) 2012-03-22
IL201564A0 (en) 2010-05-31
TWI423805B (zh) 2014-01-21
KR101088219B1 (ko) 2011-11-30
CA2687265C (en) 2012-12-04
CA2687265A1 (en) 2008-11-20
CL2008001230A1 (es) 2009-05-22
AU2008251692A1 (en) 2008-11-20
CN101679439B (zh) 2013-09-11
MA31433B1 (fr) 2010-06-01
JP5503532B2 (ja) 2014-05-28
CO6241109A2 (es) 2011-01-20

Similar Documents

Publication Publication Date Title
GT200900292A (es) "inhibidores de cinasa p70 s6"
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
ECSP088296A (es) Compuestos terapéuticos
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
CR9851A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
CR9786A (es) Compuestos de bencimidazol-tiofeno
HN2011000357A (es) Composiciones y metodos para anticuerpos que que se dirigen a la proteina de complemento c5
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
GT201200165A (es) Triazolopiridinas
UY30681A1 (es) Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos.
CR20140544A (es) Compuestos para inhibir la progresión mitotica
CR11333A (es) cis-IMIDAZOLINAS QUIRALES
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
ECSP11011344A (es) Nuevos anticuerpos anti-?5?1 y sus usos
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
UY30460A1 (es) Compuestos terapéuticos
UY30304A1 (es) Moduladores de mglur5 i
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
UY28745A1 (es) Nuevos compuestos
CO6630181A2 (es) Composiciones y métodos para uso de anticuerpos terapéuticos de lrp6( proteina relacionada con lipoproteínas de baja densidad 6)
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
UY30308A1 (es) Moduladores de mglur5 v